City

Bethesda (1)

Columbus (1)

Liege (1)

New York (1)

Overall Status

Recruiting (2)

Available (1)

Completed (1)

Enrolling by invitation (1)

Phase

phase 1/phase 2 (1)

phase 3 (1)

Sponsor

Cyprium Therapeutics, Inc. (3)

Laurent Servais (1)

Stephen G. Kaler, MD (1)

Collaborator

Centre Hospitalier Universitaire de Liege (1)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)

National Center for Complementary and Integrative Health (NCCIH) (1)

University of Liege (1)

Intervention

copper histidinate (1)

copper histidine (1)

droxidopa (1)

long term follow-up (1)

placebo (1)

Study Documents

Intervention Type

drug (4)

other (1)

Funder Type

Industry (3)

Other (2)

Study Type

Interventional (2)

Observational (2)

Expanded Access (1)

menkes disease

Showing 1 - 5 of 5

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Baby Detect : Genomic Newborn Screening

Recruiting

Congenital Adrenal Hyperplasia
+126 more

Liege, Wallonia, Belgium

CRMN, Hôpital La Citadelle

Jan 24, 2023

Long Term Follow-up on Menkes Disease Patients

Enrolling by invitation

Menkes Disease

Long Term Follow-Up

New York, New York

Cyprium Study Team

Jul 14, 2022

Menkes Disease Trial (Copper Histidinate)

Available

Menkes Disease

Copper Histidinate

(no location specified)

Mar 7, 2022

Menkes Disease, Occipital Horn Syndrome Trial in Columbus (Droxidopa, Placebo)

Recruiting

Menkes Disease
Occipital Horn Syndrome

Droxidopa
Placebo

Columbus, Ohio

Nationwide Children's Hospital

Jul 22, 2021

Menkes Disease, Occipital Horn Syndrome, Unexplained Copper Deficiency Trial run by the (Copper Histidine)

Completed

Menkes Disease
+2 more

Copper Histidine

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Nov 17, 2020